Topics
Diffuse midline glioma | Treatment | Targeted therapy | Tyrosine kinase inhibitors
Home > Publications > Topics > Diffuse midline glioma > Treatment > Targeted therapy > Tyrosine kinase inhibitors
McKay CJL, Mayoh C, Power P, Jessop S, Sriharan S, Staunton J,
Trinder S, Zhukova N, Mignone C, Govender D, Alvaro F, Downie P,
Hansford JR, Hassall T, Valvi S, Mateos MK, Barahona P, Gifford
AJ, Tax G, Tsoli M, Dolman EM, Wong M, Cowley M, Marshall GM,
Trahair TN, Ekert PG, Haber M, Tyrell V, Lau LMS, Manoharan N,
Ziegler DS, Khuong-Quang DA.
Precision-guided
therapy in H3K27-altered diffuse midline glioma.
Nat
Commun. 2026 May 19. doi:
10.1038/s41467-026-73304-9. PMID:
42156385. Trial
registration ID:
NCT03336931. ˍ